Evidence map›Paper›PMID 40342829›Full record

ArticleFrontiers in oncology2025

Efficacy and safety of TACE combined with TKIs and PD-1 inhibitors in HCC patients with prior TIPS.

Kai Xiong, Kuiyuan Huang, Yulong Liu, Huajin Pang, Peng Chen, Yalu Zheng, Tengzheng Li, Zhangyun Li, Moran Zhang, Dandan Zheng and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kai Xiong *Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Kuiyuan Huang *Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Yulong LiuDepartment of Vascular Intervention, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Huajin PangDivision of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Peng ChenState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yalu ZhengDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Tengzheng LiDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Zhangyun LiDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Moran ZhangDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Dandan ZhengDepartment of Radiation Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China.
Xiaohong HuangDepartment of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Mingrong CaoDepartment of Hepatobiliary and pancreatic Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Qiang LiDepartment of Hepatobiliary and pancreatic Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Junjie LiangDepartment of Hepatobiliary and pancreatic Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Huizhen FanDepartment of Gastroenterology, The People's Hospital of Yichun City, Yichun, Jiangxi, China.
Deju LiDepartment of Vascular Surgery, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Jian SunDepartment of Hepatobiliary and pancreatic Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Zhili WenDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Yuchuan JiangDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To compare the efficacy and safety of TACE combined with TKIs and PD-1 inhibitors between HCC patients with and without prior TIPS. Methods: This retrospective propensity score matching (PSM) study included advanced HCC patients treated with prior TIPS followed by TKIs, PD-1 inhibitors, and TACE between January 2021 and January 2023. Patients were matched with a control group of HCC patients who had not undergone TIPS (non-TIPS). Outcome measures included objective response rate (ORR) using modified RECIST (mRECIST v1.1), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety assessed by CTCAE v5.0. Results: A total of 172 patients were included before PSM. After PSM, 42 patients with prior TIPS were matched with 71 non-TIPS patients. ORR was 31.0% in the TIPS group and 57.7% in the non-TIPS group (p = 0.007), Both PFS and OS were longer in the non-TIPS group, with a median PFS of 7.9 months for TIPS patients versus 12.3 months for non-TIPS patients (hazard ratio [HR] = 2.253, p < 0.001), and a median OS of 13.5 months versus 21.1 months, respectively (HR = 2.282, p = 0.002). Treatment-related adverse events showed no significant differences between the two groups. Conclusion: TACE combined with TKIs and PD-1 inhibitors showed lower efficacy in HCC patients with prior TIPS, but it remains a viable option, providing a favorable safety profile and effective disease control.

Indexed as

hepatocellular carcinomaPD-1 inhibitorstransarterial chemoembolizationtransjugular intrahepatic portosystemic shunttyrosine kinase inhibitors

Identifiers

PMID40342829
PMCPMC12058502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.